Reference information

Historical FDA context for magnetic-field devices.

This page keeps the requested historical timeline. Each milestone relates to a particular device category and labelled use.

Important: This historical context is not a statement that CellVolt or the Simply Reset service is FDA approved, cleared or authorised for any condition. It is not medical advice and does not promise an individual outcome.
  1. 1979

    Bone-growth stimulation for non-union fractures

    Historical FDA authorisation for a specific electromagnetic bone-growth device category and a defined fracture indication.

    Source: Cadossi R, Massari L, Racine-Avila J, Aaron RK. Pulsed Electromagnetic Field Stimulation of Bone Healing and Joint Preservation. JAAOS Global Research & Reviews. 2020.

    Open source
  2. 1987

    Postoperative pain and oedema device use

    A historical, device- and indication-specific regulatory milestone described in the PEMF literature.

    Source: Waldorff EI, Zhang N, Ryaby JT. Pulsed Electromagnetic Field Applications: A Corporate Perspective. Journal of Orthopaedic Translation. 2017.

    Open source
  3. 1998

    Muscle stimulation and urinary incontinence devices

    A historical FDA milestone for particular electromagnetic device uses. It is not a general wellness-device approval.

    Source: Waldorff EI, Zhang N, Ryaby JT. Journal of Orthopaedic Translation. 2017.

    Open source
  4. 2004

    Cervical spine fusion support

    FDA authorisation for the named Cervical-Stim device in a defined adjunct spinal-fusion setting.

    Source: FDA PMA P030034, Cervical-Stim Model 505L Cervical Fusion System.

    Open source
  5. 2008

    Transcranial magnetic stimulation

    An FDA milestone for a separate transcranial magnetic stimulation device category and labelled adult indication.

    Source: Cohen SL, Bikson M, Badran BW, George MS. Brain Stimulation. 2022.

    Open source
  6. 2011

    Tumour Treating Fields

    An FDA milestone for a separate Tumour Treating Fields device category and its specific labelled use.

    Source: Rominiyi O, Vanderlinden A, Clenton SJ, et al. British Journal of Cancer. 2021.

    Open source